GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2008

Sanofi-Aventis Ups Bid for Zentiva to $2.63B

  • Sanofi-Aventis has increased its all-cash offer for Zentiva to €1.8 billion, or $2.63 billion. Zentiva’s board says that it approves this new price of 1,150 koruny, or $70.14 per share.

    If the acquisition goes through, Zentiva would add a large portfolio of generic drugs including a version of Merck & Co.’s Zoloft. The firm will become a part of sanofi-aventis Europe, which already owns roughly 24.88% of Zentiva.

    Sanofi-Aventis’ increased bid represents a 9.5% raise from the initial price of 1,050 koruny, which was made in June and rejected. The enhanced proposal is a 25.5% premium over Zentiva’s closing price on April 30, the last trading day before the intention to make an offer for Zentiva was reported.

    Sanofi-Aventis Europe has received an irrevocable and unconditional undertaking from Jiri Michal, chairman and CEO of Zentiva, to tender his shares, representing approximately 3.4% of share capital and voting rights on an undiluted basis. Other members of Zentiva’s management have undertaken to tender their Zentiva shares representing an 2.3% of Zentiva’s share capital and voting rights on an undiluted basis.

    If Zentiva withdraws its recommendation of the improved offer, a break fee of €25 million, or $36.59 million will apply.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »